Catheter Precision, Inc. (VTAK) Latest Filing Signal
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for Catheter Precision, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, Catheter Precision, Inc.'s filing signal
turned positive.
earningsVibe SuperAnalyst™ Verdict:
TURNED POSITIVE
Signal Performance — Stock Price Since Filing
30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Continuing Negative
GEMINI
Continuing Negative
CLAUDE
Continuing Negative
CHATGPT
Turned Negative
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does Catheter Precision, Inc. actually do?
Answer:
Catheter Precision, Inc. designs, manufactures, and sells innovative medical technologies focused on cardiac electrophysiology (EP). Its primary products are the VIVO System, a non-invasive 3D cardiac mapping system for identifying arrhythmia origins, and LockeT, a suture retention device for wound healing. The company targets hospitals with EP labs, aiming to improve procedural outcomes, reduce costs, and enhance patient lives. Catheter Precision markets its products domestically through direct sales and internationally via distributors, with a strategy to expand its product indications and market reach.
Question:
What are Catheter Precision, Inc.'s revenue drivers?
Answer:
Revenue is primarily driven by sales of the VIVO System and LockeT device. The company also generates revenue from software upgrade services for the VIVO System and licensing fees.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required